Nanjing Auro Biotechnology

Auro Biotechnology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the development of mRNA-based vaccines and therapeutics. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to address significant unmet needs in infectious diseases and oncology. Its lead candidate is an mRNA vaccine for COVID-19, which has progressed into clinical trials, alongside a robust pipeline targeting HPV-related cancers and respiratory viruses. Auro Biotechnology focuses on optimizing mRNA stability and delivery efficiency to enhance the immunogenicity and safety of its products. By integrating research, development, and pilot manufacturing, the company aims to establish itself as a leader in the rapidly evolving field of nucleic acid medicine.